ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $30.07 billion. The enterprise value is $30.39 billion.
| Market Cap | 30.07B |
| Enterprise Value | 30.39B |
Important Dates
The next estimated earnings date is Thursday, April 24, 2025, after market close.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | Feb 13, 2025 |
Share Statistics
ResMed has 146.58 million shares outstanding. The number of shares has decreased by -0.02% in one year.
| Current Share Class | 146.58M |
| Shares Outstanding | 146.58M |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 0.53% |
| Owned by Institutions (%) | 72.42% |
| Float | 145.64M |
Valuation Ratios
The trailing PE ratio is 24.22 and the forward PE ratio is 20.68. ResMed's PEG ratio is 1.31.
| PE Ratio | 24.22 |
| Forward PE | 20.68 |
| PS Ratio | 6.12 |
| Forward PS | 5.60 |
| PB Ratio | 5.74 |
| P/TBV Ratio | 14.96 |
| P/FCF Ratio | 21.61 |
| P/OCF Ratio | 20.37 |
| PEG Ratio | 1.31 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.75, with an EV/FCF ratio of 21.84.
| EV / Earnings | 24.34 |
| EV / Sales | 6.17 |
| EV / EBITDA | 17.75 |
| EV / EBIT | 19.48 |
| EV / FCF | 21.84 |
Financial Position
The company has a current ratio of 3.33, with a Debt / Equity ratio of 0.16.
| Current Ratio | 3.33 |
| Quick Ratio | 1.74 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 0.48 |
| Debt / FCF | 0.60 |
| Interest Coverage | 65.73 |
Financial Efficiency
Return on equity (ROE) is 25.65% and return on invested capital (ROIC) is 16.30%.
| Return on Equity (ROE) | 25.65% |
| Return on Assets (ROA) | 13.89% |
| Return on Invested Capital (ROIC) | 16.30% |
| Return on Capital Employed (ROCE) | 24.81% |
| Revenue Per Employee | $493,665 |
| Profits Per Employee | $125,121 |
| Employee Count | 9,980 |
| Asset Turnover | 0.70 |
| Inventory Turnover | 1.91 |
Taxes
In the past 12 months, ResMed has paid $286.27 million in taxes.
| Income Tax | 286.27M |
| Effective Tax Rate | 18.65% |
Stock Price Statistics
The stock price has increased by +10.28% in the last 52 weeks. The beta is 0.75, so ResMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.75 |
| 52-Week Price Change | +10.28% |
| 50-Day Moving Average | 231.12 |
| 200-Day Moving Average | 230.74 |
| Relative Strength Index (RSI) | 29.91 |
| Average Volume (20 Days) | 972,708 |
Short Selling Information
The latest short interest is 8.73 million, so 5.95% of the outstanding shares have been sold short.
| Short Interest | 8.73M |
| Short Previous Month | 9.71M |
| Short % of Shares Out | 5.95% |
| Short % of Float | 5.99% |
| Short Ratio (days to cover) | 8.59 |
Income Statement
In the last 12 months, ResMed had revenue of $4.93 billion and earned $1.25 billion in profits. Earnings per share was $8.47.
| Revenue | 4.93B |
| Gross Profit | 2.91B |
| Operating Income | 1.56B |
| Pretax Income | 1.26B |
| Net Income | 1.25B |
| EBITDA | 1.71B |
| EBIT | 1.56B |
| Earnings Per Share (EPS) | $8.47 |
Balance Sheet
The company has $521.94 million in cash and $839.74 million in debt, giving a net cash position of -$317.79 million or -$2.17 per share.
| Cash & Cash Equivalents | 521.94M |
| Total Debt | 839.74M |
| Net Cash | -317.79M |
| Net Cash Per Share | -$2.17 |
| Equity (Book Value) | 5.25B |
| Book Value Per Share | 35.77 |
| Working Capital | 1.98B |
Cash Flow
In the last 12 months, operating cash flow was $1.48 billion and capital expenditures -$84.56 million, giving a free cash flow of $1.39 billion.
| Operating Cash Flow | 1.48B |
| Capital Expenditures | -84.56M |
| Free Cash Flow | 1.39B |
| FCF Per Share | $9.49 |
Margins
Gross margin is 59.02%, with operating and profit margins of 31.67% and 25.35%.
| Gross Margin | 59.02% |
| Operating Margin | 31.67% |
| Pretax Margin | 31.16% |
| Profit Margin | 25.35% |
| EBITDA Margin | 34.75% |
| EBIT Margin | 31.67% |
| FCF Margin | 28.25% |
Dividends & Yields
This stock pays an annual dividend of $2.12, which amounts to a dividend yield of 1.03%.
| Dividend Per Share | $2.12 |
| Dividend Yield | 1.03% |
| Dividend Growth (YoY) | 10.11% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 25.03% |
| Buyback Yield | 0.02% |
| Shareholder Yield | 1.06% |
| Earnings Yield | 4.15% |
| FCF Yield | 4.63% |
Analyst Forecast
The average price target for ResMed is $253.88, which is 23.74% higher than the current price. The consensus rating is "Buy".
| Price Target | $253.88 |
| Price Target Difference | 23.74% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 8.63% |
| EPS Growth Forecast (5Y) | 14.76% |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 12.76 and a Piotroski F-Score of 8.
| Altman Z-Score | 12.76 |
| Piotroski F-Score | 8 |